SCHEMBL4749281

SCHEMBL4749281

COCOc1cc(F)ccc1C

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.47
FFAR4 Q5NUL3 1/20 0.47
SLC6A4 P31645 10/20 0.39
HTR2A P28223 1/20 0.39
KCNH2 Q12809 1/20 0.39
PTPN1 P18031 1/20 0.38
HTR2C P28335 1/20 0.36
KCNN4 O15554 1/20 0.35
SLC6A2 P23975 8/20 0.35
SLC6A3 Q01959 6/20 0.35
TSHR P16473 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
GRM5 P41594 1/20 0.34
CYP2D6 P10635 1/20 0.33
GAA P10253 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30755347 1.00 FFAR1 (0.47) FFAR1FFAR4SLC6A4HTR2AKCNH2
SCHEMBL25974302 0.83 FFAR1 (0.46) FFAR1FFAR4SLC6A4HTR2AKCNH2
SCHEMBL546111 0.82 TDP1 (0.38) KCNN4TDP1
SCHEMBL6832641 0.80 FFAR1 (0.49) FFAR1FFAR4SLC6A4HTR2AKCNH2
SCHEMBL13069269 0.80 FFAR1 (0.49) FFAR1FFAR4SLC6A4HTR2AKCNH2
SCHEMBL10111073 0.80 TSHR (0.51) TSHRSMN1; SMN2GAATDP1
SCHEMBL394047 0.79 FFAR1 (0.46) FFAR1FFAR4SLC6A4GAA
SCHEMBL29385804 0.79 FFAR1 (0.46) FFAR1FFAR4SLC6A4GAA
SCHEMBL9901812 0.78 GAA (0.41) PTPN1TSHRSMN1; SMN2GAATDP1
SCHEMBL2475470 0.78 MEN1 (0.48) FFAR1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034123-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS INC (US) 2026-02-05 US disclosed
US-20210355110-A1 THYROID HORMONE RECEPTOR AGONISTS InventisBio Co., Ltd. (CN) 2021-11-18 US disclosed
CN-101610675-A Chemical compounds quinoline derivant and they purposes as agricultural chemicals SYNGENTA PARTICIPATIONS AG (CH) 2009-12-23 CN disclosed
WO-2008121602-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034123-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CDK2, CDK1, CDK20 FFAR1 3730/4885FFAR4 4178/4885SLC6A4 4399/4885
US-20210355110-A1 THYROID HORMONE RECEPTOR AGONISTS TSHR, THRA, TRHR FFAR1 17/4885FFAR4 16/4885SLC6A4 2014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.